Advertisement

Topics

Neurocrine gains NA rights to Bial's Ongentys for Parkinson’s disease

14:40 EST 13 Nov 2017 | Elsevier Business Intelligence

Neurocrine Biosciences Inc. licensed exclusive North American development and commercialization rights to Bial-Portela & CA S...

Original Article: Neurocrine gains NA rights to Bial's Ongentys for Parkinson’s disease

NEXT ARTICLE

More From BioPortfolio on "Neurocrine gains NA rights to Bial's Ongentys for Parkinson’s disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...